Table 3.

Cox models of predictors for survival results

Variables	Univariate			Multivariate
	HR	95% CI	p	HR	95% CI	p
LRRFS
T classificationa (T1–2 vs T3–4)	2.4	1.1–5.7	0.039	1.4	0.6–3.5	0.490
N classificationa (N0–1 vs N2–3)	7.1	2.1–24.2	0.002	5.9	1.6–21.9	0.009
Gross tumor volume (continuous)	1.008	1.004–1.013	< 0.001	1.005	1.001–1.010	0.013
Lymphocyte, % (continuous)	0.956	0.916–0.999	0.045	0.971	0.926–1.019	0.235
Monocyte, % (continuous)	1.322	1.073–1.629	0.009	1.210	0.997–1.041	0.061
DMFS
Gender (Male vs Female)	0.2	0.1–0.9	0.041	0.2	0.1–1.2	0.076
N classificationa (N0–1 vs N2–3)	3.8	1.4–10.3	0.009	3.7	1.3–9.8	0.012
Gross tumor volume (continuous)	1.006	1.002–1.011	0.005	1.003	0.998–1.008	0.223
FFS
Gender (Male vs Female)	0.3	0.1–0.8	0.016	0.4	0.1–1.2	0.104
T classificationa (T1–2 vs T3–4)	1.9	1.0–3.5	0.048	1.4	0.7–2.7	0.369
N classificationa (N0–1 vs N2–3)	4.0	1.9–8.5	< 0.001	3.9	1.6–9.0	0.001
Gross tumor volume (continuous)	1.007	1.004–1.010	< 0.001	1.002	0.998–1.006	0.270
EBV DNA (<  1500 vs ≥ 1500 copies/ml)	3.7	1.1–9.2	0.031	1.2	0.3–3.6	0.536
Monocyte, % (continuous)	1.255	1.072–1.470	0.005	1.261	1.057–1.503	0.010
OS
Age (continuous)	1.028	1.000–1.059	0.044	1.041	1.001–1.082	0.046
Educational level (≤ 12 vs > 12 year)	0.3	0.1–0.9	0.040	0.4	0.1–1.9	0.259
Charlson Comorbidity Index (0 vs ≥ 1)	2.0	1.0–4.0	0.043	2.3	0.9–6.2	0.098
T classificationa (T1–2 vs T3–4)	2.5	1.3–5.0	0.008	2.3	0.9–6.0	0.100
N classificationa (N0–1 vs N2–3)	3.8	1.7–8.3	< 0.001	7.3	1.8–29.0	0.005
Gross tumor volume (continuous)	1.007	1.004–1.011	0.001	1.002	0.995–1.008	0.639
EBV DNA (<  1500 vs ≥ 1500 copies/ml)	4.2	1.8–10.0	0.001	1.5	0.5–4.3	0.426
L/M ratio (continuous)	0.788	0.649–0.957	0.018	0.676	0.488–0.936	0.018

LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, FFS failure-free survival, OS overall survival, L/M ratio lymphocyte-to-monocyte ratio, EBV Epstein-Barr virus, HR hazard ratio, CI confidence interval

^aAccording to the AJCC 7th staging system